GLAND PHARMA LIMITED

July 31, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra
(East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: : Compliance under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") – Letter to shareholders in relation to Notice and Annual Report of the Company for FY 2025-26

Pursuant to Regulation 36(1)(b) of the SEBI Listing Regulations, letters are being sent to those shareholders who have not registered their email addresses with the Company or the Registrar and Share Transfer Agent or the Depository Participant(s), providing the weblink for accessing the Notice of the 48th Annual General Meeting and Annual Report of the Company for the financial year 2025-26.

The above referred letter in this regard is enclosed.

This is for your information and records.

Yours truly,
For Gland Pharma Limited

Pallerlamudi Sampath Kumar
Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.07.31 20:00:56 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Encl: As above

GLAND PHARMA LIMITED

Corporate Identification Number (CIN) *- L24239TG1978PLC002276*
Registered Office: *Sy. No. 143 - 148, 150 and 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal, Dundigal - Gandimaisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India*
Corporate Office: *Plot No: 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M),Sangareddy District,Hyderabad 502 307*
Tel: *+91 84556 99999;* ***E-mail id:***investors@glandpharma.com; ***Website:***www.glandpharma.com

July 31, 2026

Sub.: Notice of the 48th Annual General Meeting (AGM) of Gland Pharma Limited and Annual Report for the Financial Year 2025-26.

We are pleased to inform you that the **48th Annual General Meeting** ('AGM') of the Members of Gland Pharma Limited ('the Company') is scheduled to be held on **Tuesday, August 25, 2026, at 11.00 A.M (IST)** through Video Conferencing ('VC') facility / Other Audio Visual Means ('OAVM').

As per Regulation 36 (1) (b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations, 2015'), as amended, the web-link along with QR Code, including the exact path, where complete details of the Annual Report are available is required to be sent to those member(s) who have not registered their email address(es) either with the Company or with any of the Depositories (CDSL or NSDL) or MUFG Intime India Private Limited (Formerly Link Intime India Private Limited), Registrar & Share Transfer Agent (RTA) of the Company.

Accordingly, please find below the web-link along with QR Code, including the path where complete details of the Annual Report for the Financial Year 2025-26 are available:

Website: www.glandpharma.com

Path of Annual Report 2025-26: https://glandpharma.com/images/Gland_Pharma_AR_25-26_0726.pdf

QR Code to access the Annual Report:

48th AGM information at a glance for ready reference is provided below:

Time and date of AGM	11:00 A.M (IST), Tuesday, August 25, 2026
Cut-off date for e-voting	Tuesday, August 18, 2026
E-voting start time and date	9:00 A.M (IST), Saturday, August 22, 2026
E-voting end time and date	5:00 P.M (IST), Monday, August 24, 2026
E-voting website of NSDL	www.evoting.nsdl.com

Final Dividend Information for FY2025 - 26:

Amount of Dividend	Rs. 20/- per share
Record date	Tuesday, August 11, 2026
Payment date	On or before September 24, 2026

This letter is being sent to those member(s) who have not registered their email address(es) either with the Company or with any of the Depositories or RTA of the Company as on the cut-off date i.e.,July 24, 2026.

This is also a reminder to update KYC details pursuant to SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024, and to dematerialise physical securities. The circular issued by SEBI mandates all the listed companies to record PAN, Address with PIN code, Mobile Number, Bank Account details, Specimen Signature and choice of Nomination of security holders holding securities in physical mode. While updating Email ID is optional, the security holders are requested to register email id also to avail online services. This is applicable for all security holders holding securities in physical mode.

The formats for choice of Nomination and Updation of KYC details viz; Forms ISR-1, ISR-2, ISR-3, SH-13, SH-14 and SEBI circulars are available on our RTA website as mentioned below:
https://www.in.mpms.mufg.com>Resources > Downloads > KYC > Formats for KYC.

The aforesaid SEBI Circular also mandates that security holders holding in physical mode whose folios do not have PAN, Choice of Nomination, Contact details, Bank Account details and Specimen Signature updated, shall be eligible for any payment including dividend, interest or redemption payment in respect of such folios, only through electronic mode with effect from April 1, 2024.

Should you have any queries, please feel free to contact our investor relations department at investor.helpdesk@in.mpms.mufg.com. Further,all shareholder queries or service requests in electronic mode may be raised through our RTA's website, the link for which is https://web.in.mpms.mufg.com/helpdesk/Service_Request.html or you may contact on +91 810 811 6767.

Moreover, you are also requested to update your e mail address at the earliest either through your depository participants for electronic holding or send a communication to us / our RTA to facilitate the updation to continue receiving all important information & documents thereafter and encourage Green Initiative.

Thanking you,

Yours faithfully,
For Gland Pharma Limited

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer
ACS: 17901